RESUMEN
Fifty-five years have passed from the first description of PSP, but it is in the last decade that there has been a revolutionary change in understanding both clinical and pathophysiological aspects of this disease. Ten years ago, our knowledge about the clinical spectrum and pathophysiology of the disease was quite limited, and there was no credible clinical study on any drug treatment for this devastating disease. Today, we have discovered the wide clinical spectrum of PSP, and this led to the development of new diagnostic criteria in 2017, aiming to diagnose the disease earlier and include more phenotypes into clinical studies. Moreover, just over the past 10 years, numerous large, double-blind, clinical trials with disease-modifying agents have been conducted that provided important novel insights into disease biomarkers and progression. These studies were possible because of gained novel insights into pathophysiological processes of the disease and pave the way for the near future. In the next decade, we dare to predict the discovery of biomarkers for PSP, improvements in diagnosis using the new criteria in combination with these biomarkers, and ultimately the development of a neuroprotective therapy that could be applied to patients in a prodromal stage and spare them from this devastating disorder. © 2019 International Parkinson and Movement Disorder Society.
Asunto(s)
Parálisis Supranuclear Progresiva/terapia , Predicción , Historia del Siglo XXI , Humanos , Trastornos Parkinsonianos/diagnóstico , Trastornos Parkinsonianos/historia , Trastornos Parkinsonianos/terapia , Parálisis Supranuclear Progresiva/diagnóstico , Parálisis Supranuclear Progresiva/historiaRESUMEN
Jean-Martin Charcot (1825-1893), recognized as the founder of Neurology and the first formal teacher of nervous system diseases, died on August 16, 1893, from acute pulmonary edema secondary to myocardial infarction. In his last years, there were several descriptions of his gait and posture disorders, suggesting the diagnosis of "lower-half parkinsonism" due to cerebrovascular disease.
Asunto(s)
Trastornos Parkinsonianos/historia , Enfermedades Vasculares/historia , Enfermedad de la Arteria Coronaria/historia , Historia del Siglo XIX , Neurología/historiaAsunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/historia , Enfermedad de Parkinson/historia , Trastornos Parkinsonianos/historia , Animales , Cuerpo Estriado/efectos de los fármacos , Modelos Animales de Enfermedad , Historia del Siglo XX , Humanos , Sustancia Negra/efectos de los fármacos , Investigación Biomédica TraslacionalRESUMEN
ABSTRACT Jean-Martin Charcot (1825-1893), recognized as the founder of Neurology and the first formal teacher of nervous system diseases, died on August 16, 1893, from acute pulmonary edema secondary to myocardial infarction. In his last years, there were several descriptions of his gait and posture disorders, suggesting the diagnosis of “lower-half parkinsonism” due to cerebrovascular disease.
RESUMO Jean-Martin Charcot (1825-1893) pode ser reconhecido como o fundador da Neurologia, bem como o primeiro professor de doenças do sistema nervoso. Ele morreu no dia 16 de Agosto de 1893, em decorrência de edema agudo de pulmão, secundário a infarto agudo do miocárdio. Nos últimos anos da vida de Charcot, ocorreram várias descrições de anormalidades da sua marcha e da sua postura, sugerindo o diagnóstico de parkinsonismo vascular.
Asunto(s)
Historia del Siglo XIX , Enfermedades Vasculares/historia , Trastornos Parkinsonianos/historia , Enfermedad de la Arteria Coronaria/historia , Neurología/historiaRESUMEN
Of the multitude of medical and psychiatric conditions ascribed to Hitler both in his lifetime and since his suicide in April 1945, few are more substantiated than parkinsonism. While the timeline of the development of this condition, as well as its etiology, are debated, there is clear evidence for classic manifestations of the disease, most prominently a resting tremor but also stooped posture, bradykinesia, micrographia, and masked facial expressions, with progression steadily seen over his final years. Though ultimately speculation, some have suggested that Hitler suffered from progressive cognitive and mood disturbances, possibly due to parkinsonism, that affected the course of events in the war. Here, the authors discuss Hitler's parkinsonism in the context of the Third Reich and its eventual destruction, maintaining that ultimately his disease had little effect on the end result.
Asunto(s)
Personajes , Trastornos Parkinsonianos/historia , Trastornos Parkinsonianos/psicología , Segunda Guerra Mundial , Alemania , Historia del Siglo XX , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Walther Birkmayer, an Austrian neurologist, codiscovered the efficacy of levodopa therapy for Parkinsonism in 1961. However, little has been published regarding Birkmayer's ties to National Socialism. Through documentary review, we have determined that he was an early illegal member of the SS and the Nazi party, taking part in the "de-Jewification" of the Vienna University Clinic of Psychiatry and Neurology. He also was a leader in the Nazi racial policy office and was praised for his dedication and fanaticism despite being forced to later resign from the SS. He sought support from leading Viennese Nazis, and was able to maintain his professional status for the war's remainder. Postwar, he succeeded at reintegration personally and professionally into Austrian society, all but erasing any obvious ties to his Nazi past. His story reflects ethical transgressions regarding professional and personal behavior in response to a tyrannical regime and provides lessons for today's neuroscientists.
Asunto(s)
Levodopa/historia , Nacionalsocialismo/historia , Neurología/historia , Trastornos Parkinsonianos/historia , Austria , Historia del Siglo XX , Humanos , Levodopa/uso terapéutico , Premio Nobel , Trastornos Parkinsonianos/tratamiento farmacológico , Farmacología/historia , Segunda Guerra MundialRESUMEN
Parkinson disease is a severe degenerative disease, which is bewildering for its array of clinical features. Writers for the past five centuries have described the associated symptoms. Before the nineteenth century, Miguel de Cervantes wrote Don Quixote de la Mancha and William Shakespeare wrote several tragedies dealing with neurological manifestations that are characteristic of Parkinson disease. From the nineteenth century onward, writers including Charles Dickens, Samuel Beckett, Galway Kinnell, and Harold Pinter among others have showcased in their works classic manifestations of Parkinson disease. This literary attention has led to a greater awareness on the part of the general public regarding this disease and, in turn, has opened the doors to a better understanding of and a better respect for the patients affected by this disease.
Asunto(s)
Personajes , Literatura/historia , Medicina en la Literatura , Trastornos Parkinsonianos/historia , Drama/historia , Historia del Siglo XVI , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Literatura Moderna/historia , Poesía como Asunto/historiaAsunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina , Intoxicación por MPTP/complicaciones , Intoxicación por MPTP/historia , Trastornos Parkinsonianos/etiología , Trastornos Parkinsonianos/historia , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/administración & dosificación , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/sangre , California , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Trastornos Parkinsonianos/sangre , Trastornos Parkinsonianos/diagnósticoRESUMEN
Research into familial Parkinson's disease (PD) remained at a virtual standstill in Europe and the US for several decades until a re-challenge by Japanese neurologists regarding an autosomal recessive form of PD. In 1965, our research group at Nagoya University examined familial cases of early-onset parkinsonism characterized by autosomal recessive inheritance, diurnal fluctuation of symptoms (alleviation after sleep), foot dystonia, good response to medication, and benign course without dementia. An inborn error of metabolism in some dopamine-related pathway was suspected. The clinical study of four families with the disease, named as "early-onset parkinsonism with diurnal fluctuation (EPDF)", was published in Neurology in 1973. The pathological study of a case in 1993 revealed neuronal loss without Lewy bodies in the substantia nigra. Based on these clinical and pathological evidences, EPDF was defined as a distinct disease entity. Screening for the EPDF gene was started in 1994 in collaboration with Juntendo University. With the discovery of parkin gene in 1998, EPDF was designated as PARK2. Of our 16 families examined for gene analysis, 15 proved to be PARK2, and the remaining one, PARK6.
Asunto(s)
Trastornos Parkinsonianos/historia , Ubiquitina-Proteína Ligasas/genética , Adulto , Femenino , Historia del Siglo XX , Humanos , Masculino , Trastornos Parkinsonianos/genética , Ubiquitina-Proteína Ligasas/historia , Adulto JovenRESUMEN
PURPOSE: Given the recent paper by Jang et al. on "A Highly Pathogenic H5N1 Influenza Virus" which reported a novel animal model of parkinsonism, we aimed to perform a complete historical review of the 20th and 21st century literature on parkinsonism and neurological manifestations of influenza. SCOPE: There were at least twelve major flu pandemics reported in the literature in the 20th and 21st century. Neurological manifestations most prevalent during the pandemics included delirium, encephalitis, ocular abnormalities, amyotrophy, myelopathy, radiculopathy, ataxia and seizures. Very little parkinsonism was reported with the exception of the 1917 cases originally described by von Economo. CONCLUSIONS: To date there have been surprisingly few cases of neurological issues inclusive of parkinsonism associated with influenza pandemics. Given the recent animal model of H5N1 influenza associated parkinsonism, the medical establishment should be prepared to evaluate for the re-emergence of parkinsonism during future outbreaks.
Asunto(s)
Gripe Humana/complicaciones , Enfermedades del Sistema Nervioso/etiología , Enfermedades del Sistema Nervioso/historia , Trastornos Parkinsonianos/etiología , Trastornos Parkinsonianos/historia , Animales , Aves , Bases de Datos Factuales/estadística & datos numéricos , Historia del Siglo XVI , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Gripe Aviar , Gripe Humana/epidemiología , Gripe Humana/historia , Enfermedades del Sistema Nervioso/epidemiología , Pandemias , Trastornos Parkinsonianos/epidemiologíaRESUMEN
Inflammatory responses have been proposed as important factors in dopaminergic neuro-degeneration in Parkinsonism. Increasing evidence suggests that the alteration of the glial microenvironment induced by neuronal degeneration could be deleterious to the remaining neurons. The activation of microglia/macrophages and reactive astrocytes may have a negative effect on the surrounding parenchyma, perpetuating the neurodegenerative process. However, this alteration may also go beyond the brain parenchyma and stimulate other inflammatory changes in other systems, inducing the release of proinflammatory cytokines and probably Acute Phase Proteins (APP) and Glucocorticoids (GC). In this work we review the latest advances in the field to provide a picture of the state of the art of studies of inflammatory responses and Parkinsonism, hopefully opening up new therapeutic perspectives for patients with Parkinson's disease.
Asunto(s)
Inflamación/etiología , Trastornos Parkinsonianos/complicaciones , Trastornos Parkinsonianos/inmunología , Animales , Citocinas/metabolismo , Modelos Animales de Enfermedad , Glucocorticoides/metabolismo , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Inflamación/patología , Neuroglía/metabolismo , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/historia , Trastornos Parkinsonianos/patologíaAsunto(s)
Herpes Zóster Ótico/historia , Disinergia Cerebelosa Mioclónica/historia , Neurología/historia , Trastornos Parkinsonianos/historia , Herpes Zóster Ótico/patología , Historia del Siglo XIX , Historia del Siglo XX , Disinergia Cerebelosa Mioclónica/patología , Trastornos Parkinsonianos/patologíaRESUMEN
Rigidity is commonly defined as a resistance to passive movement. In Parkinson's disease (PD), two types of rigidity are classically recognized which may coexist, "leadpipe " and "cogwheel". Charcot was the first to investigate parkinsonian rigidity during the second half of the nineteenth century, whereas Negro and Moyer described cogwheel rigidity at the beginning of the twentieth century. Jules Froment, a French neurologist from Lyon, contributed to the study of parkinsonian rigidity during the 1920s. He investigated rigidity of the wrist at rest in a sitting position as well as in stable and unstable standing postures, both clinically and with physiological recordings using a myograph. With Gardère, Froment described enhanced resistance to passive movements of a limb about a joint that can be detected specifically when there is a voluntary action of another contralateral body part. This has been designated in the literature as the "Froment's maneuver " and the activation or facilitation test. In addition, Froment showed that parkinsonian rigidity diminishes, vanishes, or enhances depending on the static posture of the body. He proposed that in PD "maintenance stabilization " of the body is impaired and that "reactive stabilization " becomes the operative mode of muscular tone control. He considered "rigidification " as compensatory against the forces of gravity. Froment also demonstrated that parkinsonian rigidity increases during the Romberg test, gaze deviation, and oriented attention. In their number, breadth, and originality, Froment's contributions to the study of parkinsonian rigidity remain currently relevant to clinical and neurophysiological issues of PD.
Asunto(s)
Rigidez Muscular/etiología , Trastornos Parkinsonianos/fisiopatología , Investigación Biomédica/historia , Francia , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Rigidez Muscular/historia , Neurología/historia , Trastornos Parkinsonianos/historiaRESUMEN
We discovered the gene for young onset autosomal recessive parkinsonism in 1998. We were gifted two lucky episodes. This is a short history on how we were able to discover the gene in a short period. We were primarily interested in the pathogenesis of sporadic Parkinson's disease (PD). We decided to do a genetic association study using a polymorphism of manganese superoxide dismutase (Mn SOD), as it is located at the pivotal position of oxidative stress and mitochondria. While we were screening many patients, we encountered what appeared to be young onset autosomal recessive family, which appeared to be linked to the sod2 locus, which had been mapped to the long arm of chromosome 6. We did linkage analysis on 13 similar families and obtained lod score above 9. Another fortune was that while doing linkage analysis, we encountered a patient who showed complete absence of one of the microsatellite markers that we were using in the linkage analysis. We thought that the marker was likely to be located within the disease gene. We started molecular cloning using this marker as the initial probe. Eventually we were able to clone a novel gene, which we named as parkin.